NO20034705L - Aripiprazol oral lösning - Google Patents

Aripiprazol oral lösning

Info

Publication number
NO20034705L
NO20034705L NO20034705A NO20034705A NO20034705L NO 20034705 L NO20034705 L NO 20034705L NO 20034705 A NO20034705 A NO 20034705A NO 20034705 A NO20034705 A NO 20034705A NO 20034705 L NO20034705 L NO 20034705L
Authority
NO
Norway
Prior art keywords
oral solution
aripiprazole oral
aripiprazole
solution
oral
Prior art date
Application number
NO20034705A
Other languages
English (en)
Other versions
NO324606B1 (no
NO20034705D0 (no
Inventor
Prakash Parab
Joyce Chou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034705(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20034705D0 publication Critical patent/NO20034705D0/no
Publication of NO20034705L publication Critical patent/NO20034705L/no
Publication of NO324606B1 publication Critical patent/NO324606B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20034705A 2001-04-25 2003-10-21 Farmasøytisk løsning egnet for oral administrering omfattende aripiprazol. NO324606B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
PCT/US2002/013048 WO2002085366A1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (3)

Publication Number Publication Date
NO20034705D0 NO20034705D0 (no) 2003-10-21
NO20034705L true NO20034705L (no) 2003-11-28
NO324606B1 NO324606B1 (no) 2007-11-26

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034705A NO324606B1 (no) 2001-04-25 2003-10-21 Farmasøytisk løsning egnet for oral administrering omfattende aripiprazol.

Country Status (37)

Country Link
US (1) US6977257B2 (no)
EP (2) EP1381367B1 (no)
JP (1) JP4401077B2 (no)
KR (1) KR100909329B1 (no)
CN (1) CN1512884B (no)
AR (1) AR033168A1 (no)
AT (1) ATE537831T1 (no)
AU (1) AU2002254722B2 (no)
BG (1) BG66177B1 (no)
BR (1) BR0208986A (no)
CA (1) CA2445276C (no)
CY (1) CY1112606T1 (no)
CZ (1) CZ306181B6 (no)
DK (1) DK1381367T3 (no)
EE (1) EE05581B1 (no)
ES (1) ES2377855T3 (no)
GE (1) GEP20053602B (no)
HK (2) HK1058316A1 (no)
HR (1) HRP20030870B1 (no)
HU (1) HU230456B1 (no)
IL (2) IL158202A0 (no)
IS (1) IS2863B (no)
MX (1) MXPA03009728A (no)
MY (1) MY129350A (no)
NO (1) NO324606B1 (no)
NZ (1) NZ528550A (no)
PE (1) PE20021086A1 (no)
PL (1) PL206882B1 (no)
PT (1) PT1381367E (no)
RS (1) RS52082B (no)
RU (1) RU2295960C2 (no)
SK (1) SK287948B6 (no)
TW (1) TWI337865B (no)
UA (1) UA76144C2 (no)
UY (1) UY27273A1 (no)
WO (1) WO2002085366A1 (no)
ZA (1) ZA200307797B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
ES2373042T3 (es) * 2003-10-08 2012-01-30 Mallinckrodt Llc Solución de metilfenidato y procedimientos de administración y producción asociados.
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
WO2005070390A2 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Mitratapide oral solution
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
EP1808164B2 (en) * 2006-01-05 2018-07-04 Teva Pharmaceutical Industries Ltd Wet granulation method for preparing pharmaceutical compositions of aripiprazole
WO2007081367A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
ATE523602T1 (de) * 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
AR067747A1 (es) 2007-07-31 2009-10-21 Otsuka Pharma Co Ltd Metodos para producir suspension de aripiprazol y formulacion liofilizada
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8815261B2 (en) * 2009-06-19 2014-08-26 Medrx Co., Ltd. Composition for external application comprising aripiprazole and organic acid as active ingredients
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846543B (zh) * 2011-06-27 2014-11-19 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2868319A4 (en) * 2012-06-29 2016-02-24 Maruishi Pharma ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
EP2900217A1 (en) * 2012-09-26 2015-08-05 Bristol-Myers Squibb Company Apixaban liquid formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
WO2014060324A1 (en) * 2012-10-16 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S Aripiprazole formulations
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (no) * 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
CN1252003A (zh) * 1997-03-31 2000-05-03 强生消费者公司 增强药物化合物渗透作用的溶剂系统
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EP1109452A2 (en) * 1998-09-03 2001-06-27 Alcide Corporation Freeze-resistant topical germicides and methods related thereto
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation

Also Published As

Publication number Publication date
ZA200307797B (en) 2004-10-06
EE200300523A (et) 2004-02-16
YU84703A (sh) 2006-08-17
EP1381367A1 (en) 2004-01-21
CY1112606T1 (el) 2016-02-10
PE20021086A1 (es) 2002-12-14
WO2002085366A1 (en) 2002-10-31
MXPA03009728A (es) 2004-01-29
JP4401077B2 (ja) 2010-01-20
ES2377855T3 (es) 2012-04-02
CZ20032821A3 (cs) 2004-09-15
BR0208986A (pt) 2004-04-20
CN1512884B (zh) 2010-05-26
HRP20030870B1 (en) 2011-10-31
EP1381367B1 (en) 2011-12-21
NO324606B1 (no) 2007-11-26
CA2445276C (en) 2009-10-13
RU2003132426A (ru) 2005-04-20
US6977257B2 (en) 2005-12-20
EP1381367A4 (en) 2009-07-01
PL206882B1 (pl) 2010-10-29
JP2004532225A (ja) 2004-10-21
ATE537831T1 (de) 2012-01-15
BG66177B1 (bg) 2011-11-30
TWI337865B (en) 2011-03-01
AU2002254722B2 (en) 2006-11-09
PT1381367E (pt) 2012-03-01
DK1381367T3 (da) 2012-04-10
KR20030096332A (ko) 2003-12-24
EP2436384B1 (en) 2015-06-10
MY129350A (en) 2007-03-30
AR033168A1 (es) 2003-12-03
CA2445276A1 (en) 2002-10-31
HUP0303946A2 (hu) 2004-04-28
HU230456B1 (hu) 2016-07-28
CZ306181B6 (cs) 2016-09-14
IS6994A (is) 2003-10-14
IL158202A0 (en) 2004-05-12
SK12642003A3 (sk) 2004-07-07
HUP0303946A3 (en) 2005-06-28
BG108216A (bg) 2004-12-30
NO20034705D0 (no) 2003-10-21
EP2436384B2 (en) 2018-05-23
EE05581B1 (et) 2012-10-15
CN1512884A (zh) 2004-07-14
IS2863B (is) 2013-12-15
HK1168792A1 (en) 2013-01-11
PL364666A1 (en) 2004-12-13
NZ528550A (en) 2005-03-24
RU2295960C2 (ru) 2007-03-27
UA76144C2 (uk) 2006-07-17
IL158202A (en) 2008-04-13
RS52082B (sr) 2012-06-30
GEP20053602B (en) 2005-08-10
US20020193438A1 (en) 2002-12-19
SK287948B6 (sk) 2012-06-04
UY27273A1 (es) 2002-11-29
KR100909329B1 (ko) 2009-07-24
HK1058316A1 (en) 2004-05-14
EP2436384A3 (en) 2012-09-19
HRP20030870A2 (en) 2004-06-30
EP2436384A2 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
NO20034705L (no) Aripiprazol oral lösning
NL300912I2 (nl) nonacog beta pegol
NO20042121D0 (no) Kinolinforbindelse
NO2014027I2 (no) aripiprazol
DE60209734D1 (de) Tetrahydrochinolin-derivate
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
NO20014597D0 (no) Fremgangsmåte
DK1480970T3 (da) Quinolinderivater
DE10107471B4 (de) Vitrine
ATA2892002A (de) Beschlag
ATE405973T1 (de) Steckverbindung
DE10295574D2 (de) Geräusch-gesteuertes Beatmungsgerät
UA6063S (uk) Вкладиш
NO20015559D0 (no) Kreklinggel±
SE0102059D0 (sv) New combination
SE0102054D0 (sv) New Combination
NO20015321D0 (no) Ventilasjonsanlegg
ITPG20010050A1 (it) Cosmeticus universal
NO20052727D0 (no) Tetrahydrokinolinderivater
SE0100062D0 (sv) New use
SE0103291D0 (sv) New use
SE0103540D0 (sv) New Use
SE0102574D0 (sv) New Use
SE0103767D0 (sv) New use
SE0100798D0 (sv) New use

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: OTSUKA PHARMACEUTICAL CO., US

MM1K Lapsed by not paying the annual fees